Concordia Healtcare Completes Acquisition of Donnatal

Concordia Healthcare Corp.  (TSX: CXR,OTCQX: CHEHF), announced today that it has completed the previously announced acquisition of Donnatal^®, an adjunctive therapy in the treatment of irritable bowel syndrome (“IBS”) and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals.

 Mark Thompson, CEO of Concordia commented:

I am extremely pleased with this landmark achievement as it demonstrates Concordia’s ability to successfully close a transaction of this magnitude, thereby opening the Company to a new level of acquisition opportunities in the future. Further, the substantial anticipated revenue to be generated by Donnatal^® is expected to have a significant and positive impact on Concordia’s net earnings and EBITDA.

Click here to read the full press release.